← Back to Browse

Celldex Therapeutics, Inc.

CLDX • Healthcare

2
Grade F
Compass
Current Price
$32.51
Market Cap
$1.7B

About Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer.

Quality Assessment

Celldex Therapeutics, Inc. is a high-risk healthcare company with a Compass Score of 2. This stock has poor quality metrics and high risk. Not recommended for conservative investors.

Score Breakdown

The Compass Score is based on 6 quality factors identified by academic research.

Click any factor to see detailed metrics

Valuation Metrics

Click any metric for details

Technical Overview

Click any metric for details

Wall Street View

Consensus
N/A
Analysts
9
Price Target
๐Ÿ”’
Upside
๐Ÿ”’

Growth Projections

Projected EPS Growth
๐Ÿ”’
Projected Revenue Growth
๐Ÿ”’

Financial Health

Click any metric for details

Important Disclaimer

The Compass Score is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always do your own research and consider consulting a financial advisor before making investment decisions.